Targeted molecular agents are a landmark achievement in cancer treatment. The tyrosine kinase inhibitor imatinib mesylate, known for its efficacy against the BCR-ABL fusion protein in chronic myelogenous leukemia, also targets the mutant KIT protein in gastrointestinal stromal tumor (GIST). However, while imatinib is remarkably effective against metastatic GIST, it almost never induces a complete response, and tumor progression occurs at a median of approximately 20 months, limiting patient survival. The objective of the curent project is to combine immunotherapy with imatinib to improve outcomes in GIST. In a transgenic mouse model of GIST, preliminary studies have shown that the anti-tumor effects of imatinib are partially immune-mediated, and that imatinib may have enhanced anti-tumor efficacy when combined with antibody-mediated blockade of CTLA-4, an immunomodulatory protein. In the current project, we will investigate the hypothesis and immunologic mechanisms by which CTLA-4 blockade enhances the anti-tumor effects of imatinib in both murine GIST and human tumor specimens.
In Aim 1, we will determine the optimal dosing of combined imatinib and anti-CTLA-4 therapy for maximal tumor shrinkage in a mouse model of GIST.
In Aim 2, we will determine if CTLA-4 blockade increases the antigen-specific CD8 T cell response against GIST in mice.
In Aim 3, we will characterize how anti-CTLA-4 alters the imatinib-induced regulatory T cell (T Reg) response to the tumor in murine GIST.
In Aim 4, we wil determine whether human intratumoral CD8 T cells are functional against GIST. We anticipate that our findings will advance our understanding of GIST and may establish the rationale for a novel clinical trial combining molecular and immunotherapy in GIST. We expect that our work will not only improve the lives of patients with these tumors, but also be relevant to other cancers in which targeted molecular therapy is used.
Targeted molecular therapies are a landmark achievement in cancer treatment. Imatinib mesylate is one such therapy, which is remarkably effective against gastrointestinal stromal tumor (GIST), a solid cancer of the stomach and intestines, but ultimately falls short of curing the disease due to the cancer developing resistance against the drug. The goal of the current research is to determine if and how immune therapy, in the form of antibody-mediated blockade of CTLA-4, an important signaling molecule in immune cells, may enhance the anti-tumor effects of imatinib, thus providing the rationale for a new clinical trial combining molecular and immune therapy in patients with GIST, as wel as a novel treatment model that can be applied to other types of cancer in which targeted molecular therapy is used.
|Seifert, Adrian M; Zeng, Shan; Zhang, Jennifer Q et al. (2016) PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res :|
|Cohen, Noah A; Kim, Teresa S; DeMatteo, Ronald P (2016) Principles of Kinase Inhibitor Therapy for Solid Tumors. Ann Surg :|
|Cohen, Noah A; Zeng, Shan; Seifert, Adrian M et al. (2015) Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res 75:2061-70|
|Kim, Teresa S; Cavnar, Michael J; Cohen, Noah A et al. (2014) Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res 20:2350-62|
|Cavnar, Michael J; Zeng, Shan; Kim, Teresa S et al. (2013) KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med 210:2873-86|